News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

KAI Pharmaceuticals, Inc. Announces Initiation of Phase 1b Study of KAI-4169 for the Treatment of Secondary Hyperparathyroidism (SHPT)



9/27/2010 10:06:05 AM

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of the first patients in a Phase 1b study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of secondary hyperparathyroidism (SHPT), which is a frequent and serious complication of end-stage renal disease (ESRD). The Phase 1b study is a double-blind, randomized, placebo-controlled, crossover study to assess the safety and tolerability of single ascending doses of KAI-4169 in ESRD patients with SHPT undergoing hemodialysis. The study also will assess the pharmacokinetics of KAI-4169 and its effect on parathyroid hormone (PTH) and serum calcium levels.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES